Generation of monoclonal antibodies against mitocryptide‐2: toward a new strategy to investigate the biological roles of cryptides
- 29 March 2017
- journal article
- research article
- Published by Wiley in Journal of Peptide Science
- Vol. 23 (7-8) , 610-617
Abstract
We recently identified a novel family of neutrophil‐activating peptides including mitocryptide‐1 and mitocryptide‐2 (MCT‐2) that are endogenously produced from various mitochondrial proteins. Among them, MCT‐2 is an N‐formylated pentadecapeptide derived from mitochondrial cytochrome b and is found to promote neutrophilic migration and phagocytosis efficiently. Signaling mechanisms of neutrophil activation by MCT‐2 have been investigated at the cellular level, and MCT‐2 has been demonstrated to be an endogenous specific ligand for formyl peptide receptor‐2 (also referred to as formyl peptide receptor‐like 1). It was also found that MCT‐2 promoted neutrophilic functions via the activation of Gi2 proteins and phosphorylation of ERK1/2 consecutively. However, the physiological production, distribution, and functions of MCT‐2 are not yet elucidated. Here, to investigate the roles of MCT‐2 in vivo, we generated monoclonal antibodies (mAbs) against human MCT‐2 (hMCT‐2) that have two different characteristics. One mAb, NhM2A1, not only bound to the region of positions 10–15 of hMCT‐2 but also recognized its C‐terminal cleavage site that is presumably produced upon enzymatic hydrolysis of cytochrome b, indicating that NhM2A1 specifically interacts with hMCT‐2 but not its parent protein. Moreover, we succeeded in acquiring a specific neutralizing mAb, NhM2A5, which blocks the bioactivities of hMCT‐2. Specifically, NhM2A5 inhibited hMCT‐2‐induced β‐hexosaminidase release in neutrophilic/granulocytic differentiated HL‐60 cells by binding to the region of positions 5–12 of hMCT‐2. Functional analysis using obtained mAbs that specifically recognize hMCT‐2 but not its parent protein, cytochrome b, and that neutralize bioactivities of hMCT‐2 is expected to reveal the physiological roles of MCT‐2, which are presently very difficult to investigate. Copyright © 2017 European Peptide Society and John Wiley & Sons, Ltd.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology of Japan (25350971, 16K01923, 16J11227)
- Nagase Science and Technology Foundation
- Maruhachi Muramatsu
This publication has 34 references indexed in Scilit:
- Mitochondrial DAMPs Increase Endothelial Permeability through Neutrophil Dependent and Independent PathwaysPLOS ONE, 2013
- Stimulated Human Mast Cells Secrete Mitochondrial Components That Have Autocrine and Paracrine Inflammatory ActionsPLOS ONE, 2012
- Mitochondrial DNA that escapes from autophagy causes inflammation and heart failureNature, 2012
- Analyzing the Cryptome: Uncovering Secret SequencesThe AAPS Journal, 2011
- Circulating mitochondrial DAMPs cause inflammatory responses to injuryNature, 2010
- Novel endogenous peptide agonists of cannabinoid receptorsThe FASEB Journal, 2009
- Discovery of Mitocryptide-1, a Neutrophil-activating Cryptide from Healthy Porcine HeartJournal of Biological Chemistry, 2008
- Cryptide signaling: Amphiphilic peptide-induced exocytotic mechanisms in mast cellsBiochemical and Biophysical Research Communications, 2008
- Hemopressin is an inverse agonist of CB 1 cannabinoid receptorsProceedings of the National Academy of Sciences of the United States of America, 2007
- Peptides from the Amino-Terminus of Mouse Mitochondrially Encoded NADH Dehydrogenase Subunit 1 Are Potent ChemoattractantsBiochemical and Biophysical Research Communications, 1995